Publication | Open Access
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers
14
Citations
8
References
2022
Year
NCT0198555.
| Year | Citations | |
|---|---|---|
Page 1
Page 1